Medacta Group SA
SIX:MOVE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
108.4
134
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medacta Group SA
Medacta Group SA
PP&E Net
Medacta Group SA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medacta Group SA
SIX:MOVE
|
PP&E Net
€267.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Metall Zug AG
SIX:METN
|
PP&E Net
CHf156.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-4%
|
|
|
Sonova Holding AG
SIX:SOON
|
PP&E Net
CHf620.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
Straumann Holding AG
SIX:STMN
|
PP&E Net
CHf708.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Medmix Ltd
SIX:MEDX
|
PP&E Net
CHf258.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Medacta Group SA
Glance View
Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The company is headquartered in Castel San Pietro, Ticino and currently employs 1,341 full-time employees. The company went IPO on 2019-04-04. The firm develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The firm designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
See Also
What is Medacta Group SA's PP&E Net?
PP&E Net
267.3m
EUR
Based on the financial report for Dec 31, 2023, Medacta Group SA's PP&E Net amounts to 267.3m EUR.
What is Medacta Group SA's PP&E Net growth rate?
PP&E Net CAGR 5Y
15%
Over the last year, the PP&E Net growth was 22%. The average annual PP&E Net growth rates for Medacta Group SA have been 20% over the past three years , 15% over the past five years .
You don't have any saved screeners yet
